SYNOX

Humanised antibody-based drugs for the treatment, diagnosis, detection and/or prevention of cancer and/or other oncological, autoimmune and inflammatory diseases; pharmaceutical products, namely, humanised antibody emactuzumab targeting the CSF1R (colony stimulating factor 1 receptor) in cancer for the treatment of cancer and inflammatory diseases; pharmaceutical products, namely, inhibitors of CSF1R and macrophage function for the treatment of cancer and/or other oncological, autoimmune and inflammatory diseases; pharmaceutical products, namely, inhibitors of protein arginine methyl-transferase (PRMT) for the treatment of TGCT (tenosynovial giant cell tumour)/PVNS (pigmented villonodular synovitis); pharmaceutical compounds for the treatment, diagnosis, detection and/or prevention of cancer and/or other oncological, autoimmune and inflammatory diseases; pharmaceutical products, preparations and substances for the treatment, diagnosis, detection and/or prevention of cancer and/or other oncological, autoimmune and inflammatory diseases; biological preparations and substances for the treatment, diagnosis, detection and/or prevention of cancer and/or other oncological, autoimmune and inflammatory diseases